Treatment-resistant bipolar disorder (Q82351280)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16432528%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

Treatment-resistant bipolar disorder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16432528%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

Gitlin M

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16432528%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16432528%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16432528%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16432528%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16432528%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

227-240

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16432528%20AND%20SRC:MED&resulttype=core&format=json

The long-term natural history of the weekly symptomatic status of bipolar I disorder

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A review of psychosocial outcome in patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Relapse and impairment in bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Donepezil in treatment-resistant bipolar disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Mexiletine in treatment-resistant bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Treatment-resistant bipolar depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Clinical factors associated with treatment noncompliance in euthymic bipolar patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Lamotrigine: a review of its use in bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Phenytoin as an antimanic anticonvulsant: a controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Prophylactic effect of phenytoin in bipolar disorder: a controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Levetiracetam in bipolar spectrum disorders: first evidence of efficacy in an open, add- on study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A Preliminary Open-Label Study of Zonisamide Treatment for Bipolar Depression in 10 Patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Use of topiramate, a new anti-epileptic as a mood stabilizer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Open-label adjunctive topiramate in the treatment of unstable bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Tiagabine Appears Not to Be Efficacious in the Treatment of Acute Mania

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Tiagabine in treatment refractory bipolar disorder: a clinical case series.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Psychotropic drug prescription patterns among patients with bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Mood stabilizer combinations: a review of safety and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Treatment of refractory depression with high-dose thyroxine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Low doses of clozapine may stabilize treatment-resistant bipolar patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Continuation and maintenance ECT in treatment-resistant bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Electroconvulsive treatment compared with lithium in the management of manic states

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Omega-3 Eicosapentaenoic Acid in Bipolar Depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

An overview of recent findings of the Stanley Foundation Bipolar Network (Part I).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Calcium channel antagonists for the treatment of bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Calcium antagonists in mania: a double-blind study of verapamil

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Effectiveness of the combination verapamil and chlorpromazine in the treatment of severe manic or mixed patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Superiority of Lithium Over Verapamil in Mania

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Verapamil treatment for women with bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

The use of nimodipine in the treatment of mood disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Double-blind, placebo-controlled pilot study of mexiletine for acute mania or hypomania

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A perspective on the use of psychoeducation, cognitive-behavioral therapy and interpersonal therapy for bipolar patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

The current status of psychological treatments in bipolar disorders: a systematic review of relapse prevention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Psychological treatment for bipolar disorders--a review of randomised controlled trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A Randomized Trial on the Efficacy of Group Psychoeducation in the Prophylaxis of Recurrences in Bipolar Patients Whose Disease Is in Remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Integrated family and individual therapy for bipolar disorder: results of a treatment development study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Advances in the pharmacologic treatment of bipolar depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Antidepressants for bipolar depression: a systematic review of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Treatment of bipolar depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Antidepressants in bipolar disorder: the case for caution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Divalproex in the treatment of bipolar depression: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Antidepressant properties of anticonvulsant drugs for bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Pramipexole for bipolar II depression: a placebo-controlled proof of concept study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Venlafaxine monotherapy in women with bipolar II and unipolar major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001793

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001793

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16432528%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference